This is EVP-6124. Kind of reminds me or PRL-8-53/147
EVP-6124, is an oral alpha-7 nicotinic partial agonist. The alpha-7 nicotinic receptor is an acetylcholine receptor highly localized to the cortical and hippocampal regions of the brain. EVP-6124 acts as a coagonist in combination with acetylcholine to activate the receptor and enhance cognition, Dr. Ilise Lombardo explained at a meeting of the New Clinical Drug Evaluation Unit sponsored by the National Institute of Mental Health.
...
EnVivo’s preclinical research has demonstrated that memory deficits can be minimized or entirely reversed by activating the alpha-7 receptor with EVP-6124 alone or in combination with other AChE-Is in low doses (for example, donepezil). EVP-6124 has also been shown to increase the release of important neurotransmitters, notably glutamate, which is believed to be important in the pathology of schizophrenia.
EVP-6124 is being developed as a long-term treatment to restore and improve cognitive function with sustained effect in Alzheimer’s disease and schizophrenia.
...
...The phase IIb trial showed that adding once-daily EVP-6124 to standard antipsychotic medication resulted in statistically significant and clinically meaningful benefits compared with placebo in terms of global cognitive function on the CogState test.
...
EVP-6124 proved safe and well tolerated in phase II testing. There were fewer adverse events and study dropouts than with placebo.
Based on these encouraging results, two phase III studies are underway. Each of the 26-week studies will randomize roughly 700 patients with schizophrenia. The MCCB and SCoRS tests will be the coprimary endpoints.
http://www.internalm...38e782e8587b6d3
http://www.envivopha...e-nicotinic.php
Edited by Xenix, 09 November 2013 - 01:59 PM.
